



doseology

Doseology Announces Proposed Debt Settlement

Kelowna, British Columbia, January 14, 2025 – Doseology Sciences Inc. (CSE: **MOOD**) (FSE: **VU7**) (“Doseology” or the “Company”), an innovator in functional mushroom supplements, announces that it has agreed to issue an aggregate of 236,364 common shares (each a “**Share**”) at a deemed price of \$0.165 per Share, to settle \$39,000 in debt (the “**Debt Settlement**”) for past consulting services provided to the Company.

All securities issued pursuant to the Debt Settlement will be subject to a mandatory four month hold period in accordance with securities laws in Canada.

For all product locations sold and wholesale inquiring please visit [**doseology.com**](https://doseology.com).

About Doseology Sciences Inc. (CSE: **MOOD**) (OTCQB: **DOSEF**) (FSE: **VU7**)

Doseology specializes in premium functional mushroom supplements that are stacked for targeted results. Our products are science-backed and health expert-formulated, addressing today's top wellness needs. With one hundred percent mushroom fruiting bodies for maximum purity and potency, Doseology leaves no room for compromise. The liquid format ensures faster absorption for an efficient wellness experience. At Doseology, we're committed to optimizing well-being through the power of fungi, offering investors an opportunity to join our journey toward optimal wellness.

On behalf of the Board of Directors,
Daniel Vice,
Co-Founder, Director
Doseology Sciences Inc.

For further information contact:

Email: hello@doseology.com

Website: doseology.com

Forward-Looking Statements

This press release contains statements that constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward-looking information is not based on historical facts but instead reflects the Company's management's expectations, estimates or projections concerning the business of the Company's future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance

should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company's prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. For more information, investors should review the Company's filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release.

The CSE does not accept responsibility for the adequacy or accuracy of this release.